Phagodent Demonstrates Efficacy in Preventing and Treating Radiation-Induced Oral Mucositis
A clinical study involving 75 cancer patients showed that Phagodent bacteriophage gel, combined with radioprotective mouthguards, may help reduce the incidence and severity of oral mucositis during radiotherapy.
The study was conducted at the Russian Scientific Center of Roentgenoradiology between 2023 and 2026. It included 75 patients with squamous cell carcinoma of the oropharyngeal region, divided into three groups: basic dental care, standard mucositis treatment, and Phagodent gel treatment (25 patients). In the main study group, 18 patients also used individualized radioprotective mouthguards.
Key Findings
Reduced bacterial load: microbial counts decreased by 100−1,000 times. Complete elimination or substantial reductions were observed in pathogens including S. aureus, P. aeruginosa, K. pneumoniae, and A. baumannii.
Preservation of beneficial microbiota: the diversity and abundance of beneficial bacteria, including S. oralis, S. mitis, and S. sanguinis, increased.
Reduced mucositis severity: the main study group demonstrated statistically significant reductions in the incidence and severity of oral mucositis. Radioprotective mouthguards provided an additional beneficial effect.
Improved quality of life: patients reported less pain and better preservation of their ability to eat and maintain oral hygiene.
Conclusion The combined use of Phagodent gel and individualized radioprotective mouthguards demonstrated potential for preventing and treating radiation-induced oral mucositis. This approach combines targeted reduction of pathogenic bacteria with preservation of beneficial oral microbiota and protection of oral tissues.
The authors emphasize that further studies are needed to confirm these findings.
We share interesting and useful information on how bacteriophages help maintain health, maintain the microbiome, and protect against dangerous bacteria